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Abstract
The Crosstalk between a tumor and its hypoxic microenvironment has become increasingly important. However, the exact
role of UCP2 function in cancer cells under hypoxia remains unknown. In this study, UCP2 showed anti-apoptotic properties
in A549 cells under hypoxic conditions. Over-expression of UCP2 in A549 cells inhibited reactive oxygen species (ROS)
accumulation (P,0.001) and apoptosis (P,0.001) compared to the controls when the cells were exposed to hypoxia.
Moreover, over-expression of UCP2 inhibited the release of cytochrome C and reduced the activation of caspase-9.
Conversely, suppression of UCP2 resulted in the ROS generation (P=0.006), the induction of apoptosis (P,0.001), and the
release of cytochrome C from mitochondria to the cytosolic fraction, thus activating caspase-9. These data suggest that
over-expression of UCP2 has anti-apoptotic properties by inhibiting ROS-mediated apoptosis in A549 cells under hypoxic
conditions.
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Introduction
UCP2 belongs to a family of anion carrier proteins and is
expressed in the inner membrane of the mitochondria [1].
Although UCP2 over-expression has been described in various
types of cancer, including human colon cancer cells [2], thyroid
tumor [3], and hepatocellular carcinoma [4], the precise function
of UCP2 in cells remains unknown [1]. It is widely accepted that
UCP2 can be activated by reactive oxygen species (ROS), forming
part of a negative feedback mechanism that mitigates excessive
ROS production [5–8].
Abundant evidence has shown that ROS are not only the
inevitable by-products of oxygen metabolism, but also play a role in
cellular signaling in tumors cells [9–12]. In HCT116, HT29 and
HepG2, etc., over-expression of UCP2 plays an anti-apoptotic role
by modulating the generation of intracellular ROS after tumor cells
are exposed to chemotherapeutic agents [7,13,14]. Meanwhile,-
Zoltan Derdak et al [7] also demonstrated that UCP2 expression in
HCT116 human colon cancer cells decreased apoptosis induced by
mechanisms involving modulation of p53 pathway. Thus, UCP2
may play an integral role in the adaptive response of cancer cells to
chemotherapeutics. Hypoxia is a well-characterized parameter of
the tumor microenvironment that profoundly influences cancer
progression and its response to treatment [15]. Hypoxia in cancer
cells also triggers an increase in mitochondrial ROS production
[16,17]. Therefore, we hypothesize that UCP2 may play a role in
tumor cells in response to hypoxic stimuli.
Collins et al. [4] showed that increased UCP2 expression
reduced apoptosis and ROS in response to the oxidative stress
induced by hypoxia/re-oxygenation in HepG2 cells. However,
they were unable to identify the mechanism underlying this
phenomenon. The authors presumed that increased UCP2 activity
may decrease the generation of intracellular ROS in mitochondria
and stabilize the membrane, making the cell more resistant to
apoptosis. A549 cells, derived from a lung adenocarcinoma, were
chosen for the current study. To establish hypoxia, the cells were
cultured in serum-free Dulbecco’s modified Eagle’s medium
(DMEM) with CoCl2 under standard culture conditions for
24 hrs. The UCP2 levels were then regulated by over-expression
or knocked down by small interfering RNA (siRNA) in A549 cells
to confirm the function of UCP2.
Materials and Methods
Cell culture and induction of a hypoxic environment
The lung adenocarcinoma cell line A549 was chosen for this
study. A549 cells were obtained from the American Type Culture
Collection (Manassas, VA) and cultured in DMEM supplemented
with 10% fetal bovine serum (FBS), penicillin 100,000 U/l and
streptomycin 100 mg/l. To establish a hypoxic condition, the cells
were cultured in serum-free DMEM with 100 mM CoCl2 (Sigma,
USA), 150 mM CoCl2 or 200 mM CoCl2 under standard culture
conditions (5% CO2 and 37uC) for 24 hrs. In the following
experiments performed in this study for detecting the function of
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serum-free DMEM for 24 hrs.
Assessment of apoptosis
The percentage of apoptotic cells was determined by monitor-
ing the translocation of phosphatidylserine to the cell surface using
an Annexin V-FITC apoptosis detection kit (Sigma, UK)
according to the manufacturer’s instructions. Cells were evaluated
for apoptosis using a FACSCalibur flow cytometer (BD Biosci-
ences) with Annexin V–FITC and PI double staining. Fluores-
cence was measured with an excitation wavelength of 480 nm
through FL-1 (530 nm) and FL-2 filters (585 nm).
Plasmids and cell transfection
In UCP2 over-expression experiments, human skeletal muscle
total RNA was reverse transcribed, and full-length human UCP2
cDNA was amplified by PCR with sequence-specific primers. The
double-digested cDNA was then inserted into pcDNA 3.1/Zeo (-)
(sites BamHI/EcoRI) using the rapid DNA ligation kit (Roche,
USA).The siRNA againsthumanUCP2waschemicallysynthesized
by GenePharma (Shanghai, China) as the following oligonucleo-
tide sequences: sense: 59-GCACCGUCAAUGCCUACAATT-39,
antisense: 59-UUGUAGGCAUUGACGGUGCTT-39.T r a n s i e n t
transfection of the UCP2 plasmid and siRNA were performed with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). A total of 5 mgo f
plasmid or 100 pmol of siRNA containing Lipofectamine was
applied in a final volume of 0.75 ml per well in 6-well plates.
Western blotting
The cells were homogenized in a lysis buffer containing 8 M
urea, 10% SDS, 1 M DTT, and protease inhibitors. Protein
concentrations were determined using a BCA Protein Assay
Reagent Kit (Beyotime, China). The cytosolic fraction was isolated
from cells as described by Johnson [18] and Catherine Plin [19].
The levels of UCP2, cytochrome C, and caspase-9 protein were
quantified by Western blotting using the indicated antibodies in
cytosolic fraction. The primary antibody to cytochrome C was
used at a concentration of 1:500 (Abcam, UK), caspase-9 (1:500;
Abcam, UK), and UCP2 (1:500; Abcam, UK). A mouse
monoclonal anti-b-actin antibody (Sigma) was used for normali-
zation. Secondary antibodies were conjugated with horseradish
peroxidase, and the signals were detected using ECL reagent (GE
Healthcare, USA).
Real-time PCR
At the commencement of each experiment, cells were harvested
at the indicated time points for the extraction of RNA, and 2 mgo f
total RNA was reverse transcribed into cDNA (TRizol, Invitrogen;
MLV Reverse transcriptase, Promega). To measure mRNA
expression of UCP2, one-step RT-PCR using the SYBR Green
PCR Master Mix kit (Applied Biosystems) was used according to
the manufacturer’s instructions. The following primers were used:
UCP2, forward: 59- GTCGGAGATACCAAAGCAC -39, reverse:
59- ATGGCATTACGAGCAACA -39. b-actin was used as an
internal reference.
ROS measurement
The generation of intracellular ROS was examined by flow
cytometry using an ROS assay kit (Applygen Co. Ltd., China).
Cells (1610
5) were incubated with 10 mM DCFH-DA in complete
medium for 30 min at 37uC to allow cellular incorporation. The
cells were then washed and resuspended in 1 mL of PBS. Single
cells were then analyzed by flow cytometry (BD Biosciences) with
an emission wavelength of 502 nm and an excitation wavelength
of 530 nm. A total of 10,000 cells were counted per sample.
Statistical analysis
Data are expressed as the mean 6 standard error (SE). The
SPSS 16.0 software package was used for statistical analysis, and
Student’s t test was applied for comparison of the means of the two
groups of experimental data. An analysis of variance (ANOVA)
was applied to compare the means of multiple groups of
measurement data. Significance was defined as P,0.05.
Results
The relationship between the expression of UCP2 and
HIF-1a accumulation at different levels of hypoxia in vitro
Hypoxia can be generated by oxygen deprivation or by the
addition of CoCl2 [20]. Hypoxia was induced by adding CoCl2 to
serum-free DMEM for 24 hrs. As seen in Figure 1A, the
expression of HIF-1a gradually increased as the oxygen level
decreased, confirming that hypoxia could be generated by the
addition of CoCl2. The protein expression level of UCP2 was
detected by Western blot, and UCP2 expression increased in a
dose-dependent manner that was correlated to the extent of
hypoxia observed in vitro (Figure 1B).
The relationship between apoptosis and different levels
of hypoxia in vitro
When being exposed exposure to hypoxia at three different
concentrations of CoCl2, cancer cells showed a dose-dependent
increase in apoptosis based on the Annexin V–PI binding assay.
Compared to the normoxic condition, the amount of apoptosis
significantly increased following the addition of 150 mM CoCl2
(P=0.032; Figure 1C).
Over-expression or knockdown of UCP2 via transfection
with over-expression plasmid or siRNA
Given that UCP2 protein expression is very low under
normoxic conditions, we evaluated the function of UCP2 siRNA
under hypoxia. Under these conditions, UCP2 mRNA concen-
tration and protein expression was significantly reduced in UCP2-
siRNA-transfected A549 cells compared to the controls (P,0.001;
Figure 2 A and B). Thus, the siRNA resulted in the potent
inhibition of UCP2 expression in A549 cells under hypoxic
conditions. To validate the over-expression, UCP2 was detected
by Western blotting and real-time PCR under normoxic
conditions. UCP2 mRNA concentrations and protein expression
levels were significantly increased compared to that of pcDNA 3.1-
control-transfected cells (P,0.001; Figure 2 C and D).
The relationship between over-expressed UCP2 and anti-
apoptotic function
Cellular apoptosis was detected by Annexin V–FITC/PI
staining. Knockdown of UCP2 under hypoxic conditions signif-
icantly increased apoptosis compared to the control-siRNA-
treated cells (P,0.001; Figure 3 A). Conversely, under the same
hypoxic conditions, over-expression of UCP2 significantly de-
creased the level of apoptosis (P,0.001; Figure 3 A).
Increasing evidence has shown that UCP2 is activated by ROS
and mitigates excessive ROS production in the form of a negative
feedback mechanism [5–8]. Therefore, the levels of ROS were
detected in A549 cells with over-expressed or suppressed UCP2
underhypoxicconditions.IntracellularROS levelsweresignificantly
increased in cells with suppressed UCP2 compared to the control
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were lower than that of the control cells under the same hypoxic
conditions (P,0.001; Figure 3B).
The mitochondrial dysfunction associated with ROS-mediated
cell death induced the activation of pro-apoptotic proteins such as
cytochrome C, which was released from the mitochondria into the
cytosol [21] and led to caspase-dependent or caspase-independent
apoptosis. in UCP2-siRNA-transfected A549 cells, which are
known to have very little UCP2 protein under hypoxic conditions,
the amount of cytosolic cytochrome C was significantly increased
(Figure 3 C). Cytochrome C activated several members of the
caspase family, most prominently the initiator, caspase-9. We
found that caspase-9 expression was increased in A549 cells
compared to the controls (Figure 3D). Furthermore, over-
expression of UCP2 inhibited the release of cytochrome C
(Figure 3C) and reduced the activation of caspase-9 (Figure 3
D). These results suggest that UCP2 could regulate the release of
cytochrome C and the activation of caspase-9.
Figure 1. A549 cells were cultured in serum-free DMEM under the following conditions: normoxia, 100 mM CoCl2, 150 mM CoCl2,o r
200 mM CoCl2 for 24 hrs. A: Western blot analysis of HIF-1a in A549 cells under different levels of hypoxia (n=3). B: Western blot analysis of UCP2
in A549 cells under different levels of hypoxia (n=3). C: The relationship between apoptosis and hypoxia in A549 cells. Data are mean 6 SEM (n=5).
*P,0.05, compared with normoxic conditions.
doi:10.1371/journal.pone.0030714.g001
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UCP2 belongs to a family of anion carrier proteins and is
expressed in the inner membrane of mitochondria [1]. Numerous
studies have indicated that UCP2 expression is upregulated in
several tumor types [2–4]. Immunohistochemical studies using
clinical tissue microarrays demonstrated that the frequency and
intensity of UCP2 staining was correlated with the degree of
neoplastic changes in the colon. Although UCP2 was rarely
detected in hyperplastic polyps (11%), it was present in tubular
adenomas (58.8%) and colon adenocarcinomas (86.0%) [2].
Hypoxia is a well-characterized parameter of the tumor
microenvironment that profoundly influences cancer progression
and its response to treatment [15]. In addition, hypoxia may
control the expression of several target genes involved in many
aspects of cancer progression, including angiogenesis [22,23],
chemoresistance [24,25], apoptosis [26,27], invasion [28,29], and
metastasis [30].
Hypoxia is generated by either oxygen deprivation or the
addition of CoCl2 [20] to the cell medium. Here, hypoxia was
induced by adding CoCl2 to serum-free DMEM for 24 hrs. Our
results demonstrated that the expression of HIF-1a gradually
increased in correlation with the decreasing oxygen levels,
confirming that hypoxia was generated by the addition of CoCl2.
Hypoxia can inhibit apoptosis in cancer cells. Olga Karovic et
al. [20] showed that the toxic effects of cobalt in cells resemble that
of hypoxia. Moreover, they found no significant increase in
apoptosis when cells cultured with 10% FBS were exposed to
200 mM CoCl2, whereas cells exposed to CoCl2 (500 mM)
exhibited typical features of cell death by apoptosis. Our results
indicated that A549 cells exposed to 100 mM CoCl2 for 24 hrs
showed minor signs of cytotoxicity. However, compared to the
cells cultured under normoxic conditions, no significant increase in
the percentage of apoptotic cells was observed. In addition, the
amount of apoptosis resulting from the addition of 150 mM CoCl2
under hypoxic conditions was different from the cells cultured in
normoxic conditions. Although our results are similar to those of
Olga Karovic et al. [20], there was a difference in the
concentration of CoCl2, which induced typical features of cell
death by apoptosis. This result may be due to the use of the serum-
free DMEM under hypoxic conditions in the present study, as
Olga Karovic et al. used DMEM with serum.
The expression of UCP2 showed a dose-dependent increase
under hypoxic conditions. Given that UCP2 protein expression
was weak under normoxic conditions, we detected the function of
UCP2 siRNA under hypoxia. Compared to that of the negative
control siRNA-treated cells under hypoxic conditions, UCP2
mRNA concentration and protein expression were decreased
following UCP2 knockdown in A549 cells. The expression of
UCP2 mRNA and protein increased compared to control cells,
indicating that such a strategy allowed the potent regulation of
UCP2 expression in A549 cells.
The importance of crosstalk between a type of cancer and its
hypoxic microenvironment has become increasingly recognized.
Figure 2. UCP2 levels are regulated by UCP2 expression. Data are mean 6 SEM. *P,0.05,compared with negative control cells. NC siRNA:
negative control siRNA-transfected cells; UCP2 siRNA: UCP2 siRNA-transfected cells; Ctrl: negative control pcDNA3.1-transfected cells; UCP2 over-
expression: pcDNA3.1-UCP2-transfected cells. A: UCP2 protein levels in UCP2 siRNA-transfected cells under hypoxic conditions (n=3). B:
Concentration of UCP2 mRNA in UCP2 siRNA-transfected cells under hypoxic conditions (n=5). C: UCP2 protein levels in cells with over-expressed
UCP2 under normoxic conditions (n=3). D. Concentration of UCP2 mRNA in cells with over-expressed UCP2 under normoxic conditions (n=5).
doi:10.1371/journal.pone.0030714.g002
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cancer cells under hypoxic conditions. To confirm the function of
UCP2 under hypoxia, its expression was modulated in A549 cells
under hypoxic conditions. We found that the level of apoptosis
significantly increased following knockdown of UCP2 compared
with that of the control cells, whereas the level of apoptosis
decreased in response to UCP2 over-expression. Collins et al. [4]
proved that increased expression of UCP2 reduced apoptosis and
ROS in response to oxidative stress induced by hypoxia/re-
oxygenation in HepG2 cells. In their study, however, the pathway
mediating this phenomenon was not clear. They presumed that
increased UCP2 activity may decrease the generation of
intracellular ROS mitochondria and stabilize the membrane,
making it more resistant to apoptosis.
UCP2 is a member of a family of anion carrier proteins
expressed in the inner membrane of the mitochondria, in which
the primary function is to allow the reentry of protons to the
mitochondrial matrix by dissipating the proton gradient and
subsequently decreasing ROS production [1,5,6,8]. It was
previously demonstrated that the main function of UCP2 was to
Figure 3. Altered UCP2 expression and apoptosis. Date are mean 6 SEM. *P,0.05, compared with negative control cells. NC siRNA: negative
control siRNA-transfected cells; UCP2 siRNA: UCP2 siRNA transfected cells; Ctrl: negative control pcDNA3.1-transfected cells; UCP2 over-expression:
pcDNA3.1-UCP2-transfected cells. A: Apoptosis is detected by Annexin V–FITC/PI staining(n=5). B: The levels of ROS in A549 cells with over-expressed
or suppressed UCP2 under hypoxic conditions(n=5). C: Cytochrome C in cytosolic fraction (n=3). D: Levels of the activating caspase-9 (n=3).
doi:10.1371/journal.pone.0030714.g003
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cancer cells, UCP2 may play an integral role in the adaptive
response to chemotherapeutics [7,13,14]. A drug-resistant subset
of cancer cells derived from leukemia, melanoma, and colon
cancer cells exhibited increased levels of UCP2 and diminished
susceptibility to cytotoxic effects [5,7,14,35]. In addition, in drug-
sensitive HL-60 cells (colon), UCP2 prevented ROS-induced
impairments in mitochondrial metabolism [14]. Francisca M. et al
[13] demonstrated that inhibition of UCP2 resulted in a marked
increase in the rate of mitochondrial ROS production and caused
cytotoxicity after exposure of colon cancer cells to cisplatin.
Consistent with our results, previous studies have shown that the
main function of UCP2 in cancer cells is to regulate ROS
production. We found that intracellular ROS was significantly
higher in cells with suppressed UCP2 compared to control cells,
and ROS generation in cells with over-expressed UCP2 was lower
than that of control cells under the same hypoxic conditions.
There is abundant evidence showing that the ROS are not only
the inevitable byproducts of oxygen metabolism, and they also
play a role in cellular signaling in several types of tumors [9–12].
Overproduction or accumulation of ROS decreases mitochondrial
membrane potentials and leads to the swelling and disruption of
mitochondria. Cytochrome C release could activate the family of
caspase proteins that lead to apoptosis [9–12]. Furthermore, Jee-
Youn Kim et al. [12] demonstrated that caspase-9 can be activated
by ROS without the involvement of cytochrome C release. Our
findings support the hypothesis that ROS is an important
mechanism mediating the apoptotic pathway, and our results
show the presence of high levels of cytochrome C and ROS in the
cytosol of cells lacking UCP2. The release of cytochrome C could
activate caspase-9 and increase apoptosis. Here, we found that
over-expression of UCP2 decreased intracellular ROS, inhibited
the release of cytochrome C, and decreased caspase-9 activation,
resulting in cell survival under hypoxic conditions. Other data [7]
proved that UCP2 expression in HCT116 human colon cancer
cells decreased apoptosis induced by mechanisms involving
modulation of p53 pathway, a pivotal tumor suppressor, but it
still needs other experiments to prove whether UCP2 plays anti-
apoptotic role by modulation of p53 pathway in hypoxia.
The results of this study indicated that over-expression of UCP2
has anti-apoptotic effects by inhibiting ROS-mediated apoptosis in
A549 cells under hypoxic conditions. Therefore, UCP2 may
provide a new target for the treatment of cancer cells under
hypoxia. Given that hypoxia is a normal state in tumors, its role as
an anti-apoptotic mechanism in cancer is supported by our
findings.
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